Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

Race Has Role In Incidence, Survival Of Rare Brain Tumor, Mayo Researchers Find
The incidence of a rare and deadly tumor called primary central nervous system lymphoma (PCNSL) is two times higher in black Americans, ages 20 to 49, than in white Americans, according to a Mayo Clinic study published in the June issue of Journal of Neuro-Oncology. In patients older than 49, the results were reversed. White Americans were twice as likely as black Americans to be diagnosed with PCNSL.
buy viagra
Children's Hospital Oakland Scientists First To Discover New For Harvesting Stem Cells
A groundbreaking study conducted by Children"s Hospital & Research Center Oakland is the first to reveal a new avenue for harvesting stem cells from a woman"s placenta, or more specifically the discarded placentas of healthy newborns. The study also finds there are far more stem cells in placentas than in umbilical cord blood, and they can be safely extracted for transplantation. Furthermore, it is highly likely that placental stem cells, like umbilical cord blood and bone marrow stem cells, can be used to cure chronic blood-related disorders such as sickle cell disease, thalassemia, and leukemia.
News of the day
New Study Results Verify That PNH Cells Are Found In Majority Of Patients With Bone Marrow Failure Syndromes
Paroxysmal nocturnal hemoglobinuria (PNH) cells are present in the majority of patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), and other bone marrow failure syndromes (BMF), according to interim results from 5,285 patients enrolled in the EXPLORE trial. EXPLORE (EXamination of PNH, by Level Of CD59 on REd and white blood cells) is the first large multicenter study to determine the frequency of PNH cells in these patient populations using a central laboratory conducting a high sensitivity test for PNH cells. The findings from EXPLORE will be presented tomorrow at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). The EXPLORE trial was sponsored by Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN).
Public Health

Mersana Reports Preliminary Phase 1 Results Of XMT-1001 In Patients With Advanced Solid Tumors

Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is a broad-spectrum cytotoxic, based on camptothecin (CPT), conjugated to Mersana"s biodegradable polymer platform, Fleximer(R). Ten of 37 evaluable patients dosed to date demonstrated evidence of stable disease and seven patients had prolonged stable disease for at least 12 weeks. The study has also demonstrated that XMT-1001 can be safely given to patients. Toxicities such as hemorrhagic cystitis and serious diarrhea were not observed in this preliminary assessment. In addition, a favorable pharmacokinetic profile was observed. "We are encouraged by the favorable safety and pharmacokinetic profile demonstrated by XMT-1001 thus far," said Julie Olson, Chief Executive Officer of Mersana. "These preliminary results build on our preclinical studies, which showed that XMT-1001 has greater efficacy in human tumor xenograft models than comparable doses of irinotecan, an agent with a similar mechanism of action as camptothecin and that is approved to treat patients with colon cancer. We look forward to advancing XMT-1001 into a Phase 2 trial in a solid tumor indication." About the XMT-1001 Preliminary Study The Phase 1 trial is an open label, dose escalation study of XMT-1001 administered as an IV infusion once every three weeks in patients with advanced solid tumors. The objectives of the study are to determine the maximum tolerated dose (MTD) as well as to assess safety and pharmacokinetics. The maximum tolerated dose is not yet defined and accrual to the study continues. ASCO Poster Information "A Phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors." By E. Sausville, L. Garbo, G. J. Weiss, S. Anthony, D. Shkolny, A. V. Yurkovetskiy, C. Bethune, R. J. Fram; University of Maryland, Baltimore, MD; New York Oncology Hematology, Albany, NY; TGen Clinical Research Services, Scottsdale, AZ; Mersana Therapeutics, Inc., Cambridge, MA; Covance Bioanalytical, Madison, WI About Fleximer(R) The key component of Mersana"s platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Fleximer(R) technology improves the therapeutic index of existing compounds by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized by solubility in water, with stability in common manufacturing procedures. About Mersana Therapeutics, Inc. Mersana Therapeutics employs its biodegradable polymer platform (Fleximer(R)) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas. Fleximer(R) and Mersana(R) are registered trademarks of Mersana Therapeutics, Inc. Mersana Therapeutics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009